{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:16Z","timestamp":1791442996409,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alkermes Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40263-020-00745-1","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T14:03:34Z","timestamp":1593785014000},"page":"961-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study"],"prefix":"10.1007","volume":"34","author":[{"given":"Peter J.","family":"Weiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"von Moltke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Wehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjie","family":"Hard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Marandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Walling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"issue":"Suppl 14","key":"745_CR1","first-page":"27","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27\u201330.","journal-title":"J Clin Psychiatry"},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adherence"},{"key":"745_CR3","unstructured":"Aristada [package insert]. Waltham, MA: Alkermes, Inc.; 2018."},{"issue":"8","key":"745_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4088\/JCP.14m09741","volume":"76","author":"HY Meltzer","year":"2015","unstructured":"Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"745_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/JCP.0000000000000691","volume":"37","author":"ML Hard","year":"2017","unstructured":"Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289\u201395.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"745_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40263-017-0447-7","volume":"31","author":"ML Hard","year":"2017","unstructured":"Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017;31(7):617\u201324.","journal-title":"CNS Drugs"},{"key":"745_CR7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, DSM-5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-5. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"745_CR8","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"issue":"2\u20133","key":"745_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2\u20133):247\u201365.","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"745_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2125.2004.01817.x","volume":"58","author":"JF Reyes","year":"2004","unstructured":"Reyes JF, Preskorn SH, Khan A, Kumar D, Cullen EI, Perdomo CA, et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol. 2004;58(Suppl 1):50\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"745_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1177\/0091270002042012005","volume":"42","author":"F Huang","year":"2002","unstructured":"Huang F, Lasseter KC, Janssens L, Verhaeghe T, Lau H, Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol. 2002;42(12):1341\u201351.","journal-title":"J Clin Pharmacol"},{"issue":"5798","key":"745_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bmj.1.5798.463","volume":"1","author":"LF Gram","year":"1972","unstructured":"Gram LF, Overo KF. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J. 1972;1(5798):463\u20135.","journal-title":"Br Med J"},{"issue":"9","key":"745_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"745_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4088\/JCP.14m09168","volume":"75","author":"JM Kane","year":"2014","unstructured":"Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254\u201360.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"745_CR15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1185\/03007995.2013.821973","volume":"29","author":"SG Potkin","year":"2013","unstructured":"Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013;29(10):1241\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"745_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.4088\/JCP.15m10467","volume":"77","author":"HA Nasrallah","year":"2016","unstructured":"Nasrallah HA, Newcomer JW, Risinger R, Du Y, Zummo J, Bose A, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016;77(11):1519\u201325.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"745_CR17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","volume":"32","author":"E Stip","year":"2010","unstructured":"Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32(Suppl 1):S3\u201320.","journal-title":"Clin Ther"},{"issue":"4","key":"745_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1017\/S1092852918001104","volume":"24","author":"HA Nasrallah","year":"2019","unstructured":"Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395\u2013403.","journal-title":"CNS Spectr"},{"issue":"1","key":"745_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","volume":"150","author":"S Mallikaarjun","year":"2013","unstructured":"Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281\u20138.","journal-title":"Schizophr Res"},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"15039","DOI":"10.1038\/npjschz.2015.39","volume":"1","author":"T Peters-Strickland","year":"2015","unstructured":"Peters-Strickland T, Baker RA, McQuade RD, Jin N, Eramo A, Perry P, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039.","journal-title":"NPJ Schizophr"},{"issue":"3","key":"745_CR21","doi-asserted-by":"publisher","first-page":"19m13207","DOI":"10.4088\/JCP.19m13207","volume":"81","author":"PJ Weiden","year":"2020","unstructured":"Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active control ALPINE study. J Clin Psychiatry. 2020;81(3):19m13207.","journal-title":"J Clin Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00745-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T11:22:45Z","timestamp":1598354565000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00745-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"3 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Alkermes, Inc., Waltham, MA, USA. Funding for editorial support was provided by Alkermes, Inc., Waltham, MA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.J. Weiden, L. von Moltke, A. Wehr, and M. Hard are former employees of Alkermes, Inc., and may own stock\/options in the company; Y. Du is currently an employee of Alkermes, Inc., and may own stock\/options in the company; M. Hard is currently an employee of Moderna, Inc.; M. Marandi has received advisory and speaking fees from Alkermes, Inc.; D.P. Walling has received grants from Alkermes, Inc., Janssen, Otsuka, Forum, Lundbeck, Sunvion, Acadia, Allergan, IntraCellular, Noven, Merck, AbbVie, and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles described in the Declaration of Helsinki and Good Clinical Practice Guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}},{"value":"Each eligible, consenting study participant provided written informed consent before study entry.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}